目的:探討慢性HBV感染（CHI）不同臨床階段患者外周血T細(xì)胞狀態(tài),為CHI臨床分期和防治提供科學(xué)依據(jù)。方法:本研究收錄CHI患者,按照患者臨床癥狀將其劃分為免疫耐受（IT）、免疫活躍（IA）、免疫控制（IC）、再活化組（RA）,健康志愿者（HD）為對(duì)照組。分離外周血單個(gè)核細(xì)胞（PBMC）,使用多色流式細(xì)胞術(shù)分析患者外周血CD4⁺T細(xì)胞、CD8⁺T細(xì)胞亞群頻率和CD8⁺T細(xì)胞表面PD-1的表達(dá)量。結(jié)果:與HD相比,CHI組T細(xì)胞及亞群變化無顯著差異;RA組CD3⁺T細(xì)胞百分比顯著下降。對(duì)于CD8⁺T細(xì)胞亞型,IC和RA組初始CD8⁺T細(xì)胞（Na?ve T cell,Tn）頻率下降;IT組效應(yīng)記憶CD8⁺T細(xì)胞（Tem）頻率降低;而IC組效應(yīng)CD8⁺T細(xì)胞（Te）頻率顯著增高（P<0.05）。相較于高HBV DNA載量組（IT）,低HBV DNA載量組（IC和RA）Tn頻率降低,Te頻率增高（P<0.0... 

【文章來源】：中國(guó)免疫學(xué)雜志. 2020,36(12)北大核心CSCD

【文章頁數(shù)】：5 頁

【部分圖文】：

外周血T細(xì)胞亞型分析

與HD相比,CHI中各組PD-1+CD8+T細(xì)胞百分比均顯著增高(P<0.05);CHI中IT、IA、IC、RA組,兩兩之間比較,IA、IC組PD-1+CD8+T細(xì)胞百分比升高最為明顯,其次是RA組,與HD相比,有統(tǒng)計(jì)學(xué)意義(P<0.05)(圖3B)。圖3 CHI不同臨床階段Treg頻率及PD-1+CD8+T細(xì)胞百分比分析

圖2 CD8+T細(xì)胞亞型與HBV DNA載量的關(guān)系表1 CHI不同臨床階段患者外周血T細(xì)胞亞群分析Tab.1 Analysis of T cell subsets from PBMCs in patients with chronic HBV at different clinical stages T cell subsets Healthy donor HD Clinical stages of chronic HBV infection IT IA IC RA CD3+T(%) 69.13(53.68-79.80) 66.9(60.25-73.67) 61.35(52.13-67.10) 70.33(64.73-76.38) 52.22(34.33-62.23) CD4+T(%) 51.34(46.05-54.58) 50.12(40.18-73.63) 48.16(33.33-69.10) 54.73(43.50-75.03) 53.16(43.80-62) CD8+T(%) 35.9(29.9-40.60) 35.17(18.95-47.38) 42.37(27.25-62.43) 33.21(18.15-46.75) 38.19(30.30-52.45) CD4+/CD8+ 1.44(1.21-1.69) 1.61(0.85-3.89) 1.34(0.53-2.54) 1.93(0.96-3.83) 1.46(0.84-2.05) CD4+CD25+CD127-Treg(%) 1.96(1.41-2.60) 2.65(2.55-2.72) 4.00(3.35-4.55) 2.24(1.42-3.20) 3.34(2.34-4.76) CD4+T cell subsets Tn(%) 35.84(21.80-56.10) 28.62(20.7-47.90) 34.80(19.80-48) 27.73(10.40-41.10) 22.81(5.64-38.60) Tcm(%) 40.41(31.50-52.50) 51.32(33.20-70.30) 47.76(25.20-61.30) 45.32(32.10-63.70) 49.9(44.50-61.40) Tem(%) 22.68(11.50-34) 16.57(9.53-25.40) 15.82(11.40-23.30) 24.91(12.70-53.50) 24.72(11.60-40.90) Te(%) 1.07(0.37-2.20) 3.49(0.18-16.30) 1.61(0.51-4.19) 2.02(0.20-3.80) 2.54(0.41-6.65) CD8+T cell subsets Tn(%) 39.27(26.70-56.50) 41.19(16.40-62.40) 40.86(18.40-62.70) 27.02(17.25-42.40) 24.81(9.76-37.40) Tcm(%) 5.80(1.24-12.90) 9.62(3.21-25.00) 5.84(3.97-7.61) 8.03(4.37-10.80) 9.78(3.86-18.10) Tem(%) 28.01(13.00-38.70) 16.79(7.04-31.70) 22.8(11.90-25.10) 20.55(8.01-38.45) 20.36(8.95-34.60) Te(%) 26.89(10.90-43.80) 32.4(17.70-59.80) 33.93(26.80-47.70) 44.39(36.10-56.10) 37.40(28.70-47.60) PD-1+CD8+(%) 14.32(8.36-18.88) 18.94(12.20-26.74) 25.48(23.29-28.45) 24.47(19.26-28.92) 24.29(13.26-36.70)

【參考文獻(xiàn)】：
期刊論文
[1]慢性乙型肝炎防治指南（2019年版）[J]. 王貴強(qiáng),王福生,莊輝,李太生,鄭素軍,趙鴻,段鐘平,侯金林,賈繼東,徐小元,崔富強(qiáng),魏來.  中華實(shí)驗(yàn)和臨床感染病雜志(電子版). 2019(06)
[2]Immune response pattern varies with the natural history of chronic hepatitis B[J]. Wen-Tao Wang,Xue-Qi Zhao,Gui-Ping Li,Yi-Zhi Chen,Lin Wang,Mei-Fang Han,Wei-Na Li,Tao Chen,Guang Chen,Dong Xu,Qin Ning,Xi-Ping Zhao.  World Journal of Gastroenterology. 2019(16)
[3]Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load[J]. Hutcha Sriplung,Alan Geater,Virasakdi Chongsuvivatwong,Teerha Piratvisuth,Edward McNeil.  World Journal of Gastroenterology. 2009(27)



本文編號(hào)：3447141